کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
1359264 | 981398 | 2010 | 10 صفحه PDF | دانلود رایگان |
A series of N-thiazole substituted arylacetamides were designed on the basis of metabolic mechanism of the aminothiazole fragment as glucokinase (GK) activators for the treatment of type 2 diabetes. Instead of introducing a substituent to block the metabolic sensitive C-5 position on the thiazole core directly, a wide variety of C-4 or both C-4 and C-5 substitutions were explored. Compound R-9k bearing an iso-propyl group as the C-4 substituent was found possessing the highest GK activation potency with an EC50 of 0.026 μM. This compound significantly increased both glucose uptake and glycogen synthesis in rat primary cultured hepatocytes. Moreover, single oral administration of compound R-9k exerted significant reduction of blood glucose levels in both ICR and ob/ob mice. These promising results indicated that compound R-9k is a potent orally active GK activator, and is warranted for further investigation as a new anti-diabetic treatment.
A series of N-thiazole substituted arylacetamides were designed as metabolic stable glucokinase (GK) activators for the treatment of type 2 diabetes. Compound R-9k, with an EC50 of 0.026 μM significantly increased both glucose uptake and glycogen synthesis in rat primary cultured hepatocytes. Single oral administration of compound R-9k exerted significant reduction of blood glucose levels in both ICR and ob/ob mice.Figure optionsDownload as PowerPoint slide
Journal: Bioorganic & Medicinal Chemistry - Volume 18, Issue 11, 1 June 2010, Pages 3875–3884